460 related articles for article (PubMed ID: 33530452)
1. Transcriptome Analysis Reveals Altered Inflammatory Pathway in an Inducible Glial Cell Model of Myotonic Dystrophy Type 1.
Azotla-Vilchis CN; Sanchez-Celis D; Agonizantes-Juárez LE; Suárez-Sánchez R; Hernández-Hernández JM; Peña J; Vázquez-Santillán K; Leyva-García N; Ortega A; Maldonado V; Rangel C; Magaña JJ; Cisneros B; Hernández-Hernández O
Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33530452
[TBL] [Abstract][Full Text] [Related]
2. Sense and Antisense DMPK RNA Foci Accumulate in DM1 Tissues during Development.
Michel L; Huguet-Lachon A; Gourdon G
PLoS One; 2015; 10(9):e0137620. PubMed ID: 26339785
[TBL] [Abstract][Full Text] [Related]
3. Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy.
Wojtkowiak-Szlachcic A; Taylor K; Stepniak-Konieczna E; Sznajder LJ; Mykowska A; Sroka J; Thornton CA; Sobczak K
Nucleic Acids Res; 2015 Mar; 43(6):3318-31. PubMed ID: 25753670
[TBL] [Abstract][Full Text] [Related]
4. Reduced cytoplasmic MBNL1 is an early event in a brain-specific mouse model of myotonic dystrophy.
Wang PY; Lin YM; Wang LH; Kuo TY; Cheng SJ; Wang GS
Hum Mol Genet; 2017 Jun; 26(12):2247-2257. PubMed ID: 28369378
[TBL] [Abstract][Full Text] [Related]
5. Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.
Yadava RS; Yu Q; Mandal M; Rigo F; Bennett CF; Mahadevan MS
Hum Mol Genet; 2020 Jun; 29(9):1440-1453. PubMed ID: 32242217
[TBL] [Abstract][Full Text] [Related]
6. (CTG)n repeat-mediated dysregulation of MBNL1 and MBNL2 expression during myogenesis in DM1 occurs already at the myoblast stage.
André LM; van Cruchten RTP; Willemse M; Wansink DG
PLoS One; 2019; 14(5):e0217317. PubMed ID: 31116797
[TBL] [Abstract][Full Text] [Related]
7. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
Christou M; Wengel J; Sokratous K; Kyriacou K; Nikolaou G; Phylactou LA; Mastroyiannopoulos NP
Nucleic Acid Ther; 2020 Apr; 30(2):80-93. PubMed ID: 31873063
[TBL] [Abstract][Full Text] [Related]
8. AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1.
Stepniak-Konieczna E; Konieczny P; Cywoniuk P; Dluzewska J; Sobczak K
Nucleic Acids Res; 2020 Mar; 48(5):2531-2543. PubMed ID: 31965181
[TBL] [Abstract][Full Text] [Related]
9. A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels.
Reddy K; Jenquin JR; McConnell OL; Cleary JD; Richardson JI; Pinto BS; Haerle MC; Delgado E; Planco L; Nakamori M; Wang ET; Berglund JA
Proc Natl Acad Sci U S A; 2019 Oct; 116(42):20991-21000. PubMed ID: 31570586
[TBL] [Abstract][Full Text] [Related]
10. Choroid plexus mis-splicing and altered cerebrospinal fluid composition in myotonic dystrophy type 1.
Nutter CA; Kidd BM; Carter HA; Hamel JI; Mackie PM; Kumbkarni N; Davenport ML; Tuyn DM; Gopinath A; Creigh PD; Sznajder ŁJ; Wang ET; Ranum LPW; Khoshbouei H; Day JW; Sampson JB; Prokop S; Swanson MS
Brain; 2023 Oct; 146(10):4217-4232. PubMed ID: 37143315
[TBL] [Abstract][Full Text] [Related]
11. The CTG repeat expansion size correlates with the splicing defects observed in muscles from myotonic dystrophy type 1 patients.
Botta A; Rinaldi F; Catalli C; Vergani L; Bonifazi E; Romeo V; Loro E; Viola A; Angelini C; Novelli G
J Med Genet; 2008 Oct; 45(10):639-46. PubMed ID: 18611984
[TBL] [Abstract][Full Text] [Related]
12. Developmental insights into the pathology of and therapeutic strategies for DM1: Back to the basics.
Chau A; Kalsotra A
Dev Dyn; 2015 Mar; 244(3):377-90. PubMed ID: 25504326
[TBL] [Abstract][Full Text] [Related]
13. Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts.
Langlois MA; Lee NS; Rossi JJ; Puymirat J
Mol Ther; 2003 May; 7(5 Pt 1):670-80. PubMed ID: 12718910
[TBL] [Abstract][Full Text] [Related]
14. Genome Editing of Expanded CTG Repeats within the Human DMPK Gene Reduces Nuclear RNA Foci in the Muscle of DM1 Mice.
Lo Scrudato M; Poulard K; Sourd C; Tomé S; Klein AF; Corre G; Huguet A; Furling D; Gourdon G; Buj-Bello A
Mol Ther; 2019 Aug; 27(8):1372-1388. PubMed ID: 31253581
[TBL] [Abstract][Full Text] [Related]
15. Reversible cardiac disease features in an inducible CUG repeat RNA-expressing mouse model of myotonic dystrophy.
Rao AN; Campbell HM; Guan X; Word TA; Wehrens XH; Xia Z; Cooper TA
JCI Insight; 2021 Mar; 6(5):. PubMed ID: 33497365
[TBL] [Abstract][Full Text] [Related]
16. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy.
Ho TH; Savkur RS; Poulos MG; Mancini MA; Swanson MS; Cooper TA
J Cell Sci; 2005 Jul; 118(Pt 13):2923-33. PubMed ID: 15961406
[TBL] [Abstract][Full Text] [Related]
17. Fuchs' Endothelial Corneal Dystrophy and RNA Foci in Patients With Myotonic Dystrophy.
Mootha VV; Hansen B; Rong Z; Mammen PP; Zhou Z; Xing C; Gong X
Invest Ophthalmol Vis Sci; 2017 Sep; 58(11):4579-4585. PubMed ID: 28886202
[TBL] [Abstract][Full Text] [Related]
18. Elevation of RNA-binding protein CUGBP1 is an early event in an inducible heart-specific mouse model of myotonic dystrophy.
Wang GS; Kearney DL; De Biasi M; Taffet G; Cooper TA
J Clin Invest; 2007 Oct; 117(10):2802-11. PubMed ID: 17823658
[TBL] [Abstract][Full Text] [Related]
19. The hallmarks of myotonic dystrophy type 1 muscle dysfunction.
Ozimski LL; Sabater-Arcis M; Bargiela A; Artero R
Biol Rev Camb Philos Soc; 2021 Apr; 96(2):716-730. PubMed ID: 33269537
[TBL] [Abstract][Full Text] [Related]
20. Quantitative Methods to Monitor RNA Biomarkers in Myotonic Dystrophy.
Wojciechowska M; Sobczak K; Kozlowski P; Sedehizadeh S; Wojtkowiak-Szlachcic A; Czubak K; Markus R; Lusakowska A; Kaminska A; Brook JD
Sci Rep; 2018 Apr; 8(1):5885. PubMed ID: 29651162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]